Literatur
-
1
Alter M J.
Epidemiology and prevention of hepatitis B.
Sem Liver.
2003;
23
39-46
-
2
Chang T T, Gish R G. et al .
A comparison of entecavir and lamivudine for HBeAg-positive chronic hepatitis B.
N Engl J Med.
2006;
354
1001-1010
-
3
Chen C J, Yang H I. et al .
Risk of hepatocellular carcinoma across a biological gradient of serum hepatitis B virus DNA level.
JAMA.
2006;
295
65-73
-
4
Colonno R J, Rose R, Baldick C J. et al .
Entecavir resistance is rare in nucleoside naive patients with hepatitis B.
Hepatology.
2006;
44
1656-1665
-
5
Cornberg M, Protzer U, Dollinger M M. et al .
[Prophylaxis, Diagnosis and Therapy of Hepatitis-B-Virus-(HBV-)Infection: upgrade of the guideline, AWMF-Register 021/011].
Zschr Gastroenterol.
2007;
45
525-574
-
6
Erhardt A, Blondin D, Hauck K. et al .
Response to interferon alfa is hepatitis B virus genotype dependent: genotype A is more sensitive to interferon than genotype D.
Gut.
2005;
54
1009-1013
-
7
Ganem D, Prince A M.
Hepatitis B virus infection - natural history and clinical consequences.
N Engl J Med.
2004;
350
1118-1129
-
8
Hadziyannis S J, Papatheodoridis G V, Dimou E, Laras A, Papaioannou C.
Efficacy of long-term lamivudine monotherapy in patients with hepatitis B e antigen-negative chronic hepatitis B.
Hepatology.
2000;
32
847-851
-
9
Hadziyannis S J, Tassopoulos N C, Heathcote E J. et al .
Long-term therapy with adefovir dipivoxil for HBeAg-negative chronic hepatitis B for up to 5 years.
Gastroenterology.
2006;
131
1743-1751
-
10
Hadziyannis S J, Tassopoulos N C, Heathcote E J. et al .
Adefovir dipivoxil for the treatment of hepatitis B e antigen-negative chronic hepatitis B.
N Engl J Med.
2003;
348
800-807
-
11
Hoofnagle J H, Doo E, Liang T J, Fleischer R, Lok A S.
Management of hepatitis B.
Hepatology.
2007;
45
1056-1075
-
12
Iloeje U H, Yang H I, Su J. et al .
Predicting cirrhosis risk based on the level of circulating hepatitis B viral load.
Gastroenterology.
2006;
130
678-686
-
13
Keam S J.
Telbivudine.
Drugs.
2007;
67
1917-1929
-
14
Lai C L, Shouval D. et al .
Entecavir versus lamivudine for patients with HBeAg-negative chronic hepatitis B.
N Engl J Med.
2006;
354
1011-1020
-
15
Lau G K, Piratvisuth T, Luo K X. et al .
Peginterferon Alfa-2a, lamivudine, and the combination for HBeAg-positive chronic hepatitis B.
N Engl J Med.
2005;
352
2682-2695
-
16
Lok A S, McMahon B J.
Chronic hepatitis B.
Hepatology.
2007;
45
507-539
-
17
Marcellin P, Lau G K, Bonino F. et al .
Peginterferon alfa-2a alone, lamivudine alone, and the two in combination in patients with HBeAg-negative chronic hepatitis B.
N Engl J Med.
2004;
351
1206-1217
-
18
Rapti I, Dimou E, Mitsoula P, Hadziyannis S J.
Adding-on versus switching-to adefovir therapy in lamivudine-resistant HBeAg-negative chronic hepatitis B.
Hepatology.
2007;
45
307-313
-
19
Sherman M, Yurdaydin C, Sollano J. et al .
Entecavir for treatment of lamivudine-refractory, HBeAg-positive chronic hepatitis B.
Gastroenterology.
2006;
130
2039-2049
-
20
Thimme R, Blum H E.
Therapie der Hepatitis B.
Schweizerische Rundschau für Medizin Praxis.
2006;
95
1383-1388
-
21
Thimme R, Spangenberg H C, Blum H E.
Hepatologie 2007.
Dtsch Med Wschr.
2007;
132
1392-1395
Prof. Dr. med. R. Thimme
Medizinische Universitätsklinik Freiburg, Abteilung Innere Medizin II
Hugstetter Straße 55
79106 Freiburg
Phone: 0761/270-3280
Fax: 0761/270-3372
Email: thimme@med1.ukl.uni-freiburg.de
